Keywords:
Automated insulin delivery; Closed loop insulin delivery; Glucose control; Hyperglycemia; Hypoglycemia; Real-world evidence; Type 1 diabetes.
Abstract:
To assess the real-world performance of MiniMed™ 780G for Australians with type 1 diabetes (T1D) following advanced hybrid closed loop (AHCL) activation and to evaluate the effect of changing from MiniMed 670/770G to 780G.